Chan Tabitha Y, Tan Poh Wee, Tan Chek Wee, Tang Johann I
National University Cancer Institute, Republic of Singapore.
Radiother Oncol. 2015 Dec;117(3):459-66. doi: 10.1016/j.radonc.2015.08.013. Epub 2015 Aug 29.
This study aims to quantify dosimetric reduction to the left anterior descending (LAD) artery, heart and lung when comparing whole breast external beam radiotherapy (WBEBRT) with multicatheter accelerated partial breast irradiation (MCABPI) for early stage left breast cancer.
Planning CT data sets of 15 patients with left breast cancer receiving multicatheter brachytherapy post breast conserving surgery were used to create two independent treatment plans - WBEBRT prescribed to 50 Gy/25 fractions and MCABPI prescribed to 34 Gy/10 fractions. Dose parameters for (i) LAD artery, (ii) heart, and (iii) ipsilateral lung were calculated and compared between the two treatment modalities.
After adjusting for Equivalent Dose in 2 Gy fractions(EQD2), and comparing MCAPBI with WBEBRT, the largest dose reduction was for the LAD artery whose mean dose differed by a factor of 7.7, followed by the ipsilateral lung and heart with a factor of 4.6 and 2.6 respectively. Compared to WBEBRT, the mean MCAPBI LAD was significantly lower compared to WBEBRT (6.0 Gy vs 45.9 Gy; p<0.01). Mean MCAPBI heart D(0.1cc) (representing the dose received by the most highly exposed 0.1 cc of the risk organ, i.e. the dose peak) was significantly lower (16.3 Gy vs 50.6 Gy; p<0.01). Likewise, the mean heart dose (MHD) was significantly lower (2.3 Gy vs 6.0 Gy; p<0.01). Peak dose and mean lung dose (MLD) for ipsilateral lung was also lower for MCAPBI compared to WBEBRT (Peak dose: 22.2 Gy vs 52.0 Gy; p<0.01; MLD: 2.3 Gy vs 10.7 Gy; p<0.01).
Compared to WBEBRT, MCAPBI showed a significant reduction in radiation dose for the LAD, heart and lung. This may translate into better cardiac and pulmonary toxicities for patients undergoing MCAPBI.
本研究旨在比较早期左乳腺癌患者接受全乳外照射放疗(WBEBRT)与多导管加速部分乳腺照射(MCABPI)时,左前降支(LAD)动脉、心脏和肺部的剂量学减少情况。
使用15例左乳腺癌患者保乳手术后接受多导管近距离放疗的计划CT数据集,创建两个独立的治疗计划——WBEBRT处方剂量为50 Gy/25次分割,MCABPI处方剂量为34 Gy/10次分割。计算并比较两种治疗方式下(i)LAD动脉、(ii)心脏和(iii)同侧肺的剂量参数。
在调整2 Gy分割等效剂量(EQD2)后,将MCAPBI与WBEBRT进行比较,LAD动脉的剂量降低幅度最大,其平均剂量相差7.7倍,其次是同侧肺和心脏,分别相差4.6倍和2.6倍。与WBEBRT相比,MCAPBI的LAD平均剂量显著低于WBEBRT(6.0 Gy对45.9 Gy;p<0.01)。MCAPBI心脏D(0.1cc)(代表风险器官中暴露程度最高的0.1 cc所接受的剂量,即剂量峰值)显著更低(16.3 Gy对50.6 Gy;p<0.01)。同样,平均心脏剂量(MHD)也显著更低(2.3 Gy对6.0 Gy;p<0.01)。与WBEBRT相比,MCAPBI同侧肺的峰值剂量和平均肺剂量(MLD)也更低(峰值剂量:22.2 Gy对52.0 Gy;p<0.01;MLD:2.3 Gy对10.7 Gy;p<0.01)。
与WBEBRT相比,MCAPBI在LAD、心脏和肺部的辐射剂量显著降低。这可能会使接受MCAPBI治疗的患者心脏和肺部毒性更好。